MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

KMT2B-related disorders: Expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation

L. Cif, D. Demailly, J. Lin, K. Barwick, D. Steel, M. Sa, N. Dorison, D. Doummar, L. Lion François, P. Coubes, K. Gorman, M. Kurian (Pierre-Bénite, France)

Meeting: MDS Virtual Congress 2020

Abstract Number: 111

Keywords: Deep brain stimulation (DBS), Dystonia: Clinical features, Dystonia: Genetics

Category: Dystonia: Clinical Trials and Therapy

Objective: Clarifying clinical phenotype, molecular genetic features and evolution with deep brain stimulation (DBS) of KMT2B related disease.

Background: Heterozygous mutations in KMT2B are associated with an early-onset, progressive, often complex generalized dystonia with prominent oromandibular, laryngeal and axial involvement. Much remains to be understood about the full spectrum of this disease.

Method: Through multicentric collaboration, 51 patients with disease associated KMT2B mutations were included in the study. Dystonia evolution with DBS (n=18) was monitored and reported using the Burke Fahn Marsden’s dystonia rating scale (BFMDRS).

Results: New disease presentations with atypical patterns of dystonia evolution and non-dystonic neurodevelopmental phenotype as well as co-morbidities, including status dystonicus, intra-uterine growth retardation and endocrinopathies were identified. Analysis of this study cohort (n=51) in tandem with published cases (n=79) revealed that patients with chromosomal deletions and protein truncating variants (PTV) had a significantly higher burden of systemic disease (with earlier onset of dystonia) than those with missense variants.
 18/51 subjects had DBS for medically refractory dystonia, at a mean age of 17 years. Follow-up after DBS ranged from 0.25 to 22 years. Significant improvement of motor function and disability (BFMDRS-M & BFMDRS-D) was evident at 6 months, 1 year and last follow-up At one-year post-DBS, 50% of subjects showed BFMDRS-M & BFMDRS-D improvements of >30%. In the long-term DBS group (DBS > 5 years, n=8), improvement of >30% was maintained in 5/8 and 3/8 subjects for the BFMDRS-M and BFMDRS-D, respectively. The greatest BFMDRS-M improvements were observed for truncal and cervical dystonia, with less clinical impact on laryngeal dystonia. Improvements in gait decreased from one year to last assessment.

Conclusion: KM2TB-related disease comprises an expanding continuum from infancy to adulthood, with early evidence of genotype-phenotype correlations. Except for laryngeal dysphonia, DBS provides significant improvement and protracted clinical benefit according to symptoms distribution.

References: Coubes P, Echenne B, Roubertie A, Vayssière N, Tuffery S, Humbertclaude V, et al. [Treatment of early-onset generalized dystonia by chronic bilateral stimulation of the internal globus pallidus. Apropos of a case]. Neurochirurgie 1999;45(2):139‑44. Meyer E, Carss KJ, Rankin J, Nichols JME, Grozeva D, Joseph AP, et al. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet 2017;49(2):223‑37. Zech M, Boesch S, Maier EM, Borggraefe I, Vill K, Laccone F, et al. Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia. Am J Hum Genet 2016;99(6):1377‑87. Gorman KM, Meyer E, Kurian MA. Review of the phenotype of early-onset generalised ; progressive dystonia due to mutations in KMT2B. Review. Eur J Paediatr Neurol 2018; 22(2):245‑56. Carecchio M, Invernizzi F, Gonzàlez-Latapi P, Panteghini C, Zorzi G, Romito L, et al. Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study. Mov Disord 2019: 34(10):1516-1527.

To cite this abstract in AMA style:

L. Cif, D. Demailly, J. Lin, K. Barwick, D. Steel, M. Sa, N. Dorison, D. Doummar, L. Lion François, P. Coubes, K. Gorman, M. Kurian. KMT2B-related disorders: Expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/kmt2b-related-disorders-expansion-of-the-phenotypic-spectrum-and-long-term-efficacy-of-deep-brain-stimulation/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/kmt2b-related-disorders-expansion-of-the-phenotypic-spectrum-and-long-term-efficacy-of-deep-brain-stimulation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley